Enanta Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Enanta Pharmaceuticals han disminuido a una tasa media anual de -57.8%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido disminuyendo a una tasa media de 26.3% al año.

Información clave

-57.8%

Tasa de crecimiento de los beneficios

-57.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	-26.3%
Rentabilidad financiera	-72.0%
Margen neto	-187.8%
Próxima actualización de resultados	06 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Mar 05

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 12

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Aug 13

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Feb 24

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Feb 08

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Nov 25

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Jul 04

Enanta: Slow Drip

May 17

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Feb 04

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Nov 25

Enanta Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Analysts Just Made A Noticeable Upgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasts

Feb 11

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Enanta Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:ENTA Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	74	-138	57	159
30 Sep 23	79	-134	53	164
30 Jun 23	81	-132	52	162
31 Mar 23	81	-125	52	158
31 Dec 22	82	-121	49	157
30 Sep 22	86	-122	45	165
30 Jun 22	89	-120	41	179
31 Mar 22	92	-112	37	187
31 Dec 21	93	-101	35	186
30 Sep 21	97	-79	33	174
30 Jun 21	97	-84	31	162
31 Mar 21	94	-74	29	150
31 Dec 20	102	-58	28	141
30 Sep 20	122	-36	27	137
30 Jun 20	150	2	27	139
31 Mar 20	176	24	26	139
31 Dec 19	188	34	26	140
30 Sep 19	205	46	26	142
30 Jun 19	221	65	26	130
31 Mar 19	234	78	26	124
31 Dec 18	238	86	25	112
30 Sep 18	207	72	23	95
30 Jun 18	215	81	23	84
31 Mar 18	166	52	22	71
31 Dec 17	131	34	22	63
30 Sep 17	103	18	21	57
30 Jun 17	40	-21	20	52
31 Mar 17	46	-13	19	48
31 Dec 16	50	-10	18	44
30 Sep 16	88	22	17	40
30 Jun 16	90	29	16	36
31 Mar 16	87	33	16	31
31 Dec 15	132	63	15	28
30 Sep 15	161	79	14	23
30 Jun 15	149	68	13	21
31 Mar 15	180	116	12	20
31 Dec 14	124	82	11	19
30 Sep 14	48	34	10	19
30 Jun 14	46	35	9	18
31 Mar 14	6	-19	8	17
31 Dec 13	5	-19	7	16
30 Sep 13	32	-7	6	17
30 Jun 13	33	-3	6	17

Ingresos de calidad: ENTA actualmente no es rentable.

Margen de beneficios creciente: ENTA actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: ENTA no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 57.8% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de ENTA en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: ENTA no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: ENTA tiene una rentabilidad financiera negativa (-72.04%), ya que actualmente no es rentable.

Enanta Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Enanta Pharmaceuticals, Inc. to Report Q2, 2024 Results on May 06, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q4, 2023 Results on Nov 20, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Enanta Pharmaceuticals, Inc. to Report Q2, 2024 Results on May 06, 2024

Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to US$21.38

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 06, 2024

Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024

Independent Director recently sold US$139k worth of stock

Independent Director notifies of intention to sell stock

President recently sold US$70k worth of stock

Consensus revenue estimates decrease by 27%, EPS upgraded

New minor risk - Share price stability

Price target decreased by 11% to US$24.38

Enanta Pharmaceuticals, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Price target decreased by 7.7% to US$27.89

Consensus revenue estimates increase by 13%

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

New minor risk - Profitability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q4, 2023 Results on Nov 20, 2023

Consensus revenue estimates fall by 25%

Insufficient new directors

Enanta Pharmaceuticals, Inc. Announces Positive Data from A Phase 1 Clinical Study of Edp-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

Consensus estimates of losses per share improve by 18%

Price target decreased by 15% to US$57.40

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Enanta Pharmaceuticals, Inc. to Report Q3, 2023 Results on Aug 07, 2023

Senior VP exercised options to buy US$245k worth of stock.

President notifies of intention to sell stock

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Consensus revenue estimates fall by 34%

Key Executive notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Enanta Pharmaceuticals, Inc. to Report Q2, 2023 Results on May 08, 2023

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 02, 2023

President exercised options and sold US$919k worth of stock

Consensus revenue estimates fall by 10%

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Enanta Pharmaceuticals, Inc. to Report Q1, 2023 Results on Feb 07, 2023

Enanta Pharmaceuticals, Inc. Initiates Sprint, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Enanta Pharmaceuticals, Inc. Announces New Preclinical Data Supporting the Potential of EDP-235 for the Treatment of COVID-19

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus

Enanta Pharmaceuticals, Inc. Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus

Enanta starts mid-stage trial of EDP-938 for RSV infection

Enanta Pharmaceuticals, Inc. to Report Q4, 2022 Results on Nov 21, 2022

Price target increased to US$77.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Enanta Pharmaceuticals, Inc. Announces Appointment of Scott T. Rottinghaus to the Position of Senior Vice President and Chief Medical Officer

Enanta Pharma FQ3 2022 Earnings Preview

Enanta Pharmaceuticals, Inc. to Report Q3, 2022 Results on Aug 08, 2022

Enanta Pharmaceuticals, Inc Announces Positive Data from A Phase 1 Clinical Study of EDP-235, Its Oral 3Cl Protease Inhibitor Designed for the Treatment of Covid-19

Enanta potential COVID drug shows safety in healthy people in early-stage trial

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from Russell 2000 Growth-Defensive Index

Price target decreased to US$69.80

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

Enanta: Slow Drip

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q2, 2022 Results on May 09, 2022

Enanta Pharmaceuticals, Inc. Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals, Inc. announced delayed 10-Q filing

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 11%

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Desglose de ingresos y gastos
Beta